Case Report

Giant Hepatic Regenerative Nodule in a Patient With Hepatitis B Virus-related Cirrhosis

Long Li1,2 and Jie Feng2

1Division of Diagnostic Radiology, Department of Medical Imaging, Guangdong Provincial Corps Hospital of Chinese People’s Armed Police Forces, Guangzhou Medical University, Guangzhou, Guangdong, China; 2Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Received: 4 July 2021 | Revised: 18 September 2021 | Accepted: 22 October 2021 | Published: 4 January 2022

Abstract

Hepatic regenerative nodules are reactive hepatocellular proliferations in response to liver injury. Giant hepatic regenerative nodules of 10 cm or more are extremely rare and have only been reported in patients with biliary atresia or Alagille syndrome. A 50-year-old man presented with a pathologically confirmed giant 11.3×9.4×11.2 cm hepatic regenerative nodule and hepatitis B virus-related cirrhosis. Imaging of intrahepatic nodule included mild hyperenhancement in the portal phase of contrast-enhanced CT and the hepatobiliary phase in the gadoxetic acid-enhanced MRI scan, as well as the portal vein crossing through sign in the setting of liver cirrhosis. This case highlights the imaging characteristics of giant hepatic regenerative nodules in hepatitis cirrhosis.

Citation of this article: Li L, Feng J. Giant Hepatic Regenerative Nodule in a Patient With Hepatitis B Virus-related Cirrhosis. J Clin Transl Hepatol 2022;10(4):778–782. doi: 10.14218/JCTH.2021.00266.

Introduction

Histopathological, regenerative nodules are hyperplastic proliferations of hepatocytes in response to necrosis, altered circulations, or other stimuli. They usually occur in patients with hepatitis or alcoholic cirrhosis, vascular liver diseases such as Budd-Chiari syndrome, or cholangiopathic disorders such as biliary atresia or Alagille syndrome. Regenerative nodules are classified by size as micronodules (<3 mm) or macronodules (≥3 mm). Large regenerative nodules are usually 5 to 15 mm in diameter, but they can be 5 cm or larger. Giant nodules as larger as 5 cm have been reported in patients with liver cirrhosis, Budd-Chiari syndrome, biliary atresia, or Alagille syndrome. Giant nodules of 10 cm in diameter or more have only been reported in patients with biliary atresia or Alagille syndrome. We report a rare and unique case who presented with a giant hepatic regenerative nodule more than 10 cm in size and associated with hepatitis B virus (HBV)-related cirrhosis.

Case report

A 50-year-old man was found to have a hepatic mass suspected to be liver cancer by ultrasonography. He denied any clinical symptoms. Physical examination revealed an enlarged non-tender liver with a firm and uneven surface. The lower edge of the liver extended to the right iliac crest. The spleen was not palpable. A routine blood workup found a white blood cell count of 5.3×109/L, a red blood cell count of 4.5×1012/L, a hemoglobin level of 141 g/L, and a platelet count of 80×109/L. Liver function tests showed increased levels of alanine aminotransferase (ALT) 107.8 IU/L (reference range, 0–40 IU/L), aspartate aminotransferase (AST) 69.4 IU/L (reference range, 0–38 IU/L), alkaline phosphatase 171.3 IU/L (reference range, 30–150 IU/L), and gamma-glutamyl transferase 452.4 IU/L (reference range, 0–47 IU/L), normal serum total bilirubin, albumin, plasma prothrombin time, international normalized ratio, and ammonia. Hepatitis virus tests were positive for hepatitis B surface antigen (HBsAg), HB e antigen, HB e antibody, and HB core antibody, and negative for HB surface antibody, hepatitis C virus antibody, and hepatitis C antigen. Alpha-fetoprotein and carcinoembryonic antigen assays were negative.

A CT scan showed pronounced nodular irregularity of the liver surface, enlargement of the interlobar fissure, hypertrophy of the left lobe, and dilatation of the portal vein, with a diameter of 21.0 mm (Fig. 1). Diffuse multiple nodules of <1 cm diameter in the liver parenchyma showed slight hyperdensity on precontrast CT images and became isodense in post-contrast phases (Fig. 1). Precontrast CT showed a well-circumscribed 11.3×9.4×11.2 cm oval hypodense mass in segment VI of the liver, including a focal hypodense area extending downward to the right iliac fossa (Fig. 2A, A′). Contrast-enhanced CT showed isoenhancement in the arterial phase (Fig. 2B, B′) with slight hyperenhancement, portal vein branch crossing through the lesion in the portal phase (Fig. 2C, C′), and slight hyperenhancement in the de-
Li L. et al: Giant hepatic regenerative nodule

layed phase (Fig. 2D, D'). The focal hypodense area within the lesion was not enhanced from the arterial phase to the delayed phase.

A follow-up contrast-enhanced MRI with gadoxetic acid at 6 months found no significant differences in the size, shape, margin, internal characteristics, and three-phase contrast-enhancement patterns compared with the original CT images, except for slight hyperenhancement in the delayed 20 and 30 m hepatobiliary phases (Fig. 3). At 10.5 months after the first hospital admission, a CT-guided percutaneous biopsy resulted in pathological confirmation of a hepatic regenerative nodule (Fig. 4).

Discussion

When assessing a patient with a liver mass, noninvasive diagnosis of HBV-related cirrhosis and the imaging characteristics of hepatic regenerative nodules are important. Non-invasive diagnosis of HBV-related cirrhosis depends on calculation of the AST-to-platelet ratio index (APRI) and the fibrosis-4 score (FIB-4) using indirect markers of fibrosis such as ALT, AST and platelet count.\[\text{APRI} = \frac{(\text{AST}/\text{AST ULN})/\text{platelet count}}{\times 100} \] and the Fib-4 score = (age in years × AST)/(platelet count × √ALT). In clinical practice, liver biopsy has been replaced by noninvasive methods as APRI and FIB-4 scores and imaging.\[\text{APRI} > 2\] is recommended as the preferred noninvasive threshold to determine the presence of cirrhosis in resource-limited settings by the World Health Organization HBV guidelines. A FIB-4 >3.25 has a 97% specificity and a 65% positive predictive value for advanced fibrosis.\[\text{FIB-4} > 3.25\] However, conventional ultrasound, CT, and MRI can detect morphologic changes in the liver related to advanced fibrosis, but the methods have a limited ability to identify early-stage fibrosis.\[\text{APRI} > 2\] Our patient was positive for HBV, with an APRI of 2.283 and a FIB-4 of 4.18. CT scan showed morphological changes in the liver and the dilation of portal veins. We diagnosed HBV-related cirrhosis based on the findings.

During imaging evaluation, predominant portal perfusion was visible in dynamic contrast-enhanced imaging, including CT, MRI, and ultrasound. The vascular supply of regenerative nodules is similar to the surrounding hepatic parenchyma,\[\text{APRI} > 2\] unlike hepatocellular carcinoma (HCC), which usually shows arterial wash-in and late washout, regenerative nodules are usually isointense during the arterial and portal venous phases and become more isointense or hypointense during the equilibrium and delayed phases.\[\text{APRI} > 2\] In the hepatobiliary phase of gadoxetic acid-enhanced MRI, regenerative nodules commonly appear as isointense or mildly hyperintense signals, and not hypointense, relative to the surrounding liver parenchyma because of the preserved hepatocellular function.\[\text{APRI} > 2\] In addition to the contrast-enhancement pattern, the image of the portal vein crossing through the mass is re-
reported to be characteristic of giant hepatic regenerative nodules in the portal phase images because the nodules have normal portal tracts at the center. Therefore, hepatic regenerative nodules of various sizes should be categorized as Liver Imaging and Reporting Data System category 2, as they did not have the major and ancillary imaging features of HCC and other malignancies.

Current international guidelines recommend that all HBsAg-positive patients with cirrhosis should be routinely monitored for disease activity and progression to HCC. Recent clinical practice guidelines include gadoxetic acid-enhanced liver MRI as the first-line diagnostic and monitoring tool for hepatic nodules instead of biopsy. A single dynamic CT or MRI study rather than two dynamic imaging modalities is recommended for the diagnosis of HCC lesions of < 2 cm. Huge lesions should be considered as focal malignant transformations if major and/or ancillary imaging features of Liver Imaging and Reporting Data System category to assess HCC or other malignancies have developed. Percutaneous needle biopsies may be difficult to obtain in cases of focal malignant transformation. During the initial stage of tumor initiation, HCC may retain hepatocellular function and isointense or mildly hyperintense signals similar to regenerative nodules. For early HCC in cirrhotic livers, patients should be evaluated with multiparametric imaging, including T1 hypointensity, T2 hyperintensity, diffusion-weighted imaging hyperintensity, arterial enhancement, late wash-out, and hepatobiliary hypointensity at a size threshold of ≥ 1.5 cm on gadoxetic acid-enhanced MRI. The findings should be interpreted with care. Finally, if imaging features and laboratory results still cannot support a definitive diagnosis, a multidisciplinary team may discuss the atypical features to help to develop an appropriate approach for the patient. In conclusion, giant hepatic regenerative nodules in the background of liver cirrhosis have characteristic imaging features that can help guide clinical management and avoid unnecessary medical interventions.

**Funding**

None to declare.

**Conflict of interest**

The authors have no conflict of interests related to this publication.

**Author contributions**

Both authors, LL and FJ, contributed to the design and implementation of the study and to the analysis of the results and to the writing of the manuscript.
Li L. et al: Giant hepatic regenerative nodule

Patient consent

The patient provided written informed consent and gave permission for publication of this case report and any accompanying images.

References

[1] International working party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22(3):983–993. doi:10.1016/0270-9139(95)90324-0, PMID:7657307.
[2] Sempoux C, Balabaud C, Paradis V, Bioulac-Sage P. Hepatocellular nodules

Fig. 3. Follow-up contrast-enhanced MRI with gadoxetic acid. (A) Precontrast coronal T2-weighted image shows an oval, well-circumscribed iso-signal mass in segment VI of the liver. (B) Delayed 20 m hepatobiliary phase in the gadoxetic acid-enhanced MRI shows a slightly hyperenhanced mass and surrounding liver cirrhosis with heterogeneous. (C) Delayed 30 m hepatobiliary phase in the gadoxetic acid-enhanced MRI shows a persistent slightly hyperenhanced mass. MRI, magnetic resonance imaging.

Fig. 4. CT-guided percutaneous biopsy and pathological findings of a giant mass in segment VI of the liver (A) CT image showing a biopsy needle inserted into the margin of the mass in segment VI of the liver. (B) Hematoxylin and eosin staining indicates vacuolar degeneration in the cytoplasm of most hepatocytes, bilirubin deposition in cytoplasm of some hepatocytes, and interstitial fibrous proliferation with focal lymphocytic infiltration of portal areas. 100× magnification. (C) Anti-cytokeratin 8 immunostaining is strongly positive in hepatocytes, indicating normal and mature differentiation. 100× magnification. (D) Anti-cluster of differentiation 34 immunostaining is positive in vascular endothelial cells in portal areas and hepatic sinusoid endotheliocytes. 100× magnification. (E) Anti-alpha-fetoprotein immunostaining is negative in hepatocytes. 100× magnification. (F) Gordon and Sweet silver staining (black) shows a reticular fiber network in the subendothelial spaces of the hepatic sinusoids. 200× magnification. CT, computed tomography.
in vascular liver diseases. Virchows Arch 2018;473(1):33–44. doi:10.1007/s00428-018-2373-6, PMID:29804132.

[3] Yoon HJ, Jeon TY, Yoo SY, Kim JH, Eo H, Lee SK, et al. Hepatic tumours in children with biliary atresia: single-centre experience in 13 cases and review of the literature. Clin Radiol 2014;69(3):e113–e119. doi:10.1016/j.crad.2013.10.017, PMID:24332171.

[4] Rapp JB, Bellah RD, Maya C, Pawel BR, Anupindi SA. Giant hepatic regenerative nodules in Alagille syndrome. Pediatr Radiol 2017;47(2):197–204. doi:10.1007/s00247-016-3728-2, PMID:27796468.

[5] Andrews AR, Putra J. Central Hepatic Regenerative Nodules in Alagille Syndrome: A Clinicopathological Review. Fetal Pediatr Pathol 2021;40(1):69–79. doi:10.1080/15513815.2019.1675834, PMID:31608763.

[6] Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhotic and dysplastic hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008;28(3):747–769. doi:10.1148/radiographics.283055108, PMID:18480482.

[7] Elsayes KM, Chernyak V, Morshid AI, Tang A, Kielar AZ, Bashir MR, et al. Spectrum of Pitfalls, Pseudolesions, and Potential Misdiagnoses in Cirrhosis. AJR Am J Roentgenol 2018;211(1):87–96. doi:10.2214/AJR.18.19781, PMID:29932761.

[8] Mamone G, Carollo V, Di Piazza A, Cortis K, Degiorgio S, Miraglia R. Budd-Chiari Syndrome and hepatic regenerative nodules: Magnetic resonance findings with emphasis of hepatobiliary phase. Eur J Radiol 2019;117:25. doi:10.1016/j.ejrad.2019.05.015, PMID:31307641.

[9] World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015. Available from: https://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.

[10] Aubé C, Bazeris P, Lebigot J, Cartier V, Boursier J. Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance. Diagn Interv Imaging 2017;98(6):455–468. doi:10.1016/j.diii.2017.03.003, PMID:28461073.

[11] Jiang H, Zheng T, Duan T, Chen J, Song B. Non-invasive in vivo Imaging Grading of Liver Fibrosis. J Clin Transl Hepatol 2018;6(2):198–207. doi:10.14218/JCTH.2017.00038, PMID:29951365.

[12] Borzio M, Paladino F, Francica G. Liver carcinogenesis: diagnostic and clinical aspects of preneoplastic nodules. Hepatoma Res 2019;5:15. doi:10.20517/2394-5079.2019.11.

[13] Zech C, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioi L, et al. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 2020;30(1):370–382. doi:10.1007/s00330-019-06369-4, PMID:31385048.

[14] Shah A, Tang A, Santillan C, Sirlin C. Cirrhotic liver: What’s that nodule? The LI-RADS approach. J Magn Reson Imaging 2016;43(2):281–294. doi:10.1002/jmri.24937, PMID:25996905.

[15] Abdel Razek AAK, El-Serougy LG, Saleh GA, Shabana W, Abd El-Wahab A. Liver Imaging Reporting and Data System Version 2018: What Radiologists Need to Know. J Comput Assist Tomogr 2020;44(2):168–177. doi:10.1097/RACT.0000000000000995, PMID:32195795.

[16] Sato T, Kondo F, Ebara M, Sugiuira N, Okabe S, Sunaga M, et al. Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study. Hepatol Int 2015;9(2):330–336. doi:10.1007/s12072-015-9620-6, PMID:25788204.

[17] Chen N, Motosugi U, Sano K, Ichikawa T, Nakano M, Morisaka H, et al. Early hepatocellular carcinomas showing isointensity or hyperintensity in gadoxetic acid-enhanced, hepatocyte-phase magnetic resonance images. J Comput Assist Tomogr. 2013;37(3):466–469. doi:10.1097/RACT.0b013e3182737f99, PMID:23674023.

[18] Rhee H, Kim MJ, Park MS, Kim KA. Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI. Br J Radiol 2012;85(1018):e837–844. doi:10.1259/bjr/13212920, PMID:22553295.

[19] Kim JH, Joo J, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20(7):1009–1014. doi:10.3348/kjr.2018.0636, PMID:31270973.

[20] Xiong J, Luo J, Jian B, Wu J. Overall diagnostic accuracy of different MR imaging sequences for detection of dysplastic nodules: a systematic review and meta-analysis. Eur Radiol 2021. doi:10.1007/s00330-021-08022-5, PMID:34357448.